The Cancer Trend Most Patients Never See

Why a single lactate dehydrogenase result tells you very little — and how a pattern of LDH tests across time can show you whether your cancer is advancing, retreating, or holding steady.

IMPORTANT — Please Read Before Using This Document This material is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Statements regarding dietary supplements have not been evaluated by the FDA. Always consult your qualified healthcare practitioner before making changes to your protocol.

A Snapshot vs. a Movie

A single LDH result is a snapshot. It tells you where the number sits today — and very little else.

A series of LDH results is something else entirely. It's a movie. It tells you which direction the metabolic engine of your cancer is moving. It tells you whether your tumor burden is climbing, plateauing, or shrinking. It tells you whether your current treatment — conventional, integrative, or both — is actually working at the cellular level, often weeks before the next scan can.

That's the framing most patients never get. The result comes back. The number is "high" or "normal." The conversation moves on. But the real signal — the one that drives clinical decision-making in melanoma centers, lymphoma clinics, and germ-cell oncology — isn't the single value. It's the trend.

This article is about that trend, how to track it, and which cancers it works for.

What LDH Is and Why Cancer Cells Make So Much

Lactate dehydrogenase (LDH) is the enzyme that converts pyruvate into lactate at the end of glycolysis. Healthy cells route most glucose into the mitochondria for clean energy production via oxidative phosphorylation.

Cancer cells do something different. Nearly a century ago, Otto Warburg observed that tumor cells preferentially ferment glucose into lactate — even when oxygen is plentiful. This is the Warburg effect, now recognized as a defining metabolic hallmark of cancer.

LDH sits at the center of that switch. The more glycolytically active a tumor — the bigger, faster-growing, more hypoxic, more aggressive — the more LDH it produces. As tumor cells die, become damaged, or outgrow their blood supply, LDH leaks into the bloodstream and shows up on your lab panel.

Serum LDH therefore reflects three overlapping signals at once: tumor metabolic activity, tumor burden, and tumor cell turnover (including the necrotic core of larger tumors).

And there's a fourth layer. The lactate that cancer cells produce doesn't just leak into the bloodstream as waste. It acidifies the tumor microenvironment, suppresses T-cell function, and blunts natural killer (NK) cell activity. Patients with elevated LDH consistently show diminished antitumor immunity and respond less well to checkpoint inhibitors than patients with normal LDH.

That's why a single LDH number matters. But it's also why a pattern of LDH numbers matters far more.

Why a Series Beats a Single Reading

A one-time LDH result has three problems no one usually mentions.

First, it has no direction. A patient with LDH of 200 (within normal range) could be on the way up from 150 — meaning something is accelerating — or on the way down from 350, meaning treatment is working. The single number can't tell you which.

Second, it has noise. LDH can transiently rise from a hard workout, a bruise, a viral illness, hemolysis during the blood draw, certain medications, or a temporary liver irritation. One reading caught on an off day is misleading. Three readings in a row trending the same direction are not.

Third, it has lag. Scans are typically run every 3 months. Tumor markers specific to your cancer (CEA, PSA, CA-125, AFP, β-hCG, etc.) are often the same. LDH is cheap, fast, and can be drawn at every visit — sometimes monthly — providing a high-frequency signal that fills in the gaps between scans.

When you stack three to six LDH readings over several months and chart them, what was invisible in a single result becomes a clear trajectory. The slope tells the story.

A real-world study of patients with very high LDH (>1000 IU/L) followed over time showed that those whose LDH dropped back to normal by two months on treatment lived dramatically longer (median ~22.6 months) than those whose LDH did not (often less than 2 months). That's not a snapshot finding. That's a trend finding — and it changed how those patients were managed.

Non-Cancer Causes of Elevated LDH

LDH is found in nearly every tissue in the body and rises whenever cells are damaged — meaning many non-cancer conditions can elevate it. Common causes include hemolysis (often from a difficult blood draw),¹ heart attack,² liver disease, hepatitis, hemolytic anemias, pulmonary embolism, pneumonia (bacterial, viral, or Pneumocystis),² sepsis, kidney disease, pancreatitis, muscle injury, rhabdomyolysis, stroke, seizures, and recent strenuous exercise.³ COVID-19 elevates LDH so consistently that it has become a major severity and mortality predictor.⁴ Certain medications (aspirin, anesthetics, procainamide) can also raise LDH, and a rare benign phenomenon called macro-LDH — when LDH binds to immunoglobulin — can cause persistently high readings in completely healthy individuals.⁵ One elevated reading is almost never enough information to act on.

How to Track LDH as a Pattern

Here's the practical structure of LDH trend monitoring.

Establish a baseline before treatment. Two readings, ideally a few weeks apart, before chemotherapy, radiation, immunotherapy, or surgery begin. The average gives you a meaningful starting point that filters out one-time noise.

Repeat at every routine blood draw. LDH is part of a comprehensive metabolic panel (CMP), so in most practices it's included automatically when your oncologist orders standard labs. Make sure it appears on every panel — and that you get a copy.

This is an example of an LDH Blood Test.

This is an example of an SMAC-25 blood test.

Plot the values, don't just read them. A spreadsheet with date in one column and LDH in the next, charted as a simple line, transforms the data. Patterns invisible in a list of numbers — slow drift upward, sharp inflection points, a plateau followed by a turn — become obvious on a graph.

Pair LDH with the rest of the picture. LDH never travels alone. Track it alongside hs-CRP (inflammation), fasting insulin and HbA1c (metabolic fuel for the Warburg effect), neutrophil-to-lymphocyte ratio from a CBC with differential (immune readiness), ferritin (inflammation/iron), and your cancer-specific tumor markers. When multiple markers move in the same direction at the same time, the signal is real.

Watch for these patterns:

• Steady decline → treatment (conventional, integrative, or both) is reducing tumor burden or metabolic activity. Stay the course.
• Steady rise → something is growing or accelerating. Time to investigate before the next scheduled scan.
• Sharp spike → could be a real tumor event, but rule out non-cancer causes first: recent intense exercise, hemolysis, liver irritation from a new medication or supplement, or acute illness. Repeat the test in 1–2 weeks.
• Plateau after a decline → treatment has achieved a new steady state. Worth a conversation about what's next.
• Plateau after a rise → the engine has paused. Useful to know, but no reason to relax — track closely.

Which Cancers Reliably Elevate LDH

Not all cancers raise serum LDH in a useful, trackable way. The literature is clearest on the following — these are the cancers where LDH tracking has documented prognostic value and where a series of readings is most likely to be a useful clinical signal:

Strongest evidence — LDH formally incorporated into staging or risk classification:

• Melanoma (LDH is part of the AJCC TNM staging system for metastatic melanoma; elevated LDH defines the M1c subgroup)
• Germ cell tumors (testicular, ovarian non-seminoma; LDH is part of the IGCCCG international risk classification)
• Diffuse large B-cell lymphoma and other aggressive non-Hodgkin lymphomas (LDH is one of the five components of the International Prognostic Index, or IPI)
• Metastatic renal cell carcinoma (LDH is part of the MSKCC and IMDC risk models)

Strong evidence — consistently associated with prognosis across many studies:

• Small cell lung cancer
• Non-small cell lung cancer (especially with brain metastases)
• Gastric cancer
• Nasopharyngeal cancer
• Prostate cancer (particularly metastatic castration-resistant)
• Hepatocellular carcinoma (liver cancer)
• Pancreatic cancer
• Colorectal cancer (especially metastatic)
• Esophageal cancer
• Bladder cancer (urothelial carcinoma)
• Cervical cancer
• Acute leukemias (AML, ALL — also a marker of tumor lysis risk)
• Neuroblastoma
• Multiple myeloma — but only in high-grade, aggressive, or "lymphoma-like" variants (see below)

In meta-analyses pooling over 22,000 patients across 76 studies, elevated pretreatment LDH was associated with poor overall survival across virtually all solid tumor types studied, with the largest effect sizes in renal cell, melanoma, gastric, prostate, nasopharyngeal, and lung cancers.

Which Cancers Do Not Reliably Elevate LDH

This is the list almost no one publishes — and it's just as important as the first list. Knowing it prevents the most common LDH-tracking mistake: assuming a "normal" LDH means the cancer is gone or quiet, when in reality LDH is simply not a useful marker for that tumor.

Cancers where serum LDH is often normal even with active disease:

• Early-stage, low-grade (indolent) follicular and other indolent B-cell lymphomas — LDH is typically normal at diagnosis and only rises if the lymphoma transforms to an aggressive form
• Multiple myeloma in early or stable phases — elevated LDH is unusual and, when present, generally signals a high-grade or "lymphoma-like" variant with grave prognosis (most myeloma patients should not expect LDH elevation, even during active disease)
• Chronic lymphocytic leukemia (CLL) in early stages — LDH is usually normal until accelerated phase or Richter transformation
• Many early-stage solid tumors — most stage I and many stage II cancers don't produce enough tumor burden to raise serum LDH detectably, regardless of cancer type
• Some primary brain tumors — the blood-brain barrier limits LDH leakage into general circulation; brain-confined tumor activity may not register on a serum test
• Most thyroid cancers (differentiated papillary and follicular) — thyroglobulin is the relevant marker, not LDH
• Most low-grade prostate cancers — PSA is the relevant marker; LDH typically rises only with metastatic, castration-resistant disease
• Some breast cancers — research shows LDHB is silenced by promoter methylation in a high frequency of breast cancers, making serum LDH a less reliable single marker. Use it alongside CA 15-3, CA 27.29, and CEA, not as a standalone signal.

The honest summary: if you have one of the cancers on this second list, an LDH series is not your primary tracking tool. Don't be falsely reassured by a normal value, and don't read a small fluctuation as meaningful. Track the markers that are validated for your specific cancer, and treat LDH as one piece of a larger metabolic picture rather than as a tumor-activity gauge.

What This Looks Like in Practice — A Brief Case Sketch

Consider two hypothetical patients with metastatic melanoma starting checkpoint inhibitor therapy. Both have an elevated baseline LDH of 380 (upper limit of normal ~225).

Patient A: LDH is checked monthly. Month 1: 360. Month 2: 290. Month 3: 230. The slope is unmistakable — downward, consistent, and steep. This trend often precedes radiographic improvement on the next scan. The patient and the integrative team have actionable information weeks before imaging would confirm it: stay the course, keep building the supporting protocol.

Patient B: LDH is checked monthly. Month 1: 410. Month 2: 480. Month 3: 590. The slope is unmistakable in the other direction. This trend often precedes radiographic progression. The patient and the team have an early warning signal — time to reassess, re-investigate, and adjust before the next scan delivers the bad news.

Same starting number. Same cancer. Two completely different stories — visible only in the trend.

The Seven-Pillar PREVAIL™ Approach to a Rising LDH

When the trend is moving in the wrong direction, three of the seven pillars of the Prevail Protocol™ are most directly relevant.

P — Pinpoint Your Biology. Confirm the trend is real. Repeat the test in 1–2 weeks to rule out a non-cancer spike. Pair LDH with hs-CRP, fasting insulin/HbA1c, ferritin, CBC with differential, and your cancer-specific markers. A rising LDH alongside rising CRP and a falling lymphocyte count tells a very different story than an isolated LDH bump on a stable panel.

R — Root Your Nutrition. The Warburg engine runs on glucose. Carbohydrate restriction strategies — Kancer Keto™ and Timed Eating for Cancer™ — directly target the substrate that drives LDH production. Foods rich in polyphenols (berries, green tea, cruciferous vegetables, turmeric, dark spices) supply natural compounds with documented LDH-modulating activity.

I — Integrate Every System. This is where targeted nutraceuticals, repurposed medications, and lifestyle modalities combine. Peer-reviewed compounds with documented LDH-inhibitory or glycolysis-blocking activity include EGCG, quercetin, curcumin, berberine, resveratrol, fisetin, silibinin, and FWGE (fermented wheat germ extract). These are organized within the ONCO-ADJUNCT™ Pathways (UltraBotanica, code PREVAIL20):

• Pathway 2 — Protisorb Curcumin + Protisorb Quercetin + Frankincense
• Pathway 3 — Protisorb Berberine
• Pathway 3+ — Protisorb Berberine + FWGE
• Pathway 4 — Protisorb Fisetin + EGCG + trans-Resveratrol + Beta Glucans (PureMune)

Repurposed medications, including metformin, aspirin, mebendazole, and ivermectin, also interact with glycolytic pathways through different mechanisms. Lifestyle modalities matter too: HIIT for Cancer shifts metabolism back toward oxidative phosphorylation; infrared sauna supports detoxification and circulation; quality sleep restores immune surveillance.

Dosing decisions belong with your qualified practitioner. The Prevail Protocol™ deliberately includes no dosages — application is individualized.

The Bottom Line

A single LDH result is a snapshot. A series is a movie. The movie tells you what your cancer is actually doing — often weeks before scans can confirm it.

If you have one of the cancers on the first list above, ask your oncology team to draw LDH at every routine visit, get a copy of every result, and plot the values yourself. The trend will speak — and you'll be the first one to hear it.

If you have one of the cancers on the second list, don't be misled by a normal LDH. Track the markers that are validated for your specific cancer, and use LDH as one piece of a broader metabolic picture rather than the headline marker.

Either way, you stop guessing and start strategizing.

Take the Next Step

If you want a structured way to apply this to your own situation, the Prevail Starter™ is the foundational guide that introduces the Seven-Pillar PREVAIL™ framework, the seven cancer labs to ask your oncology team for (LDH included), and the integrative-oncology principles every cancer patient should know.

👉 [Download the Prevail Starter™ Guide — Free]

For a personalized strategy built around your specific diagnosis, labs, and treatment plan, book a 1-on-1 Cancer Coaching session and we'll build your full Prevail Protocol™ together.

👉 Book Your Discovery Call — prevailovercancer.com/coaching

Prevail Over Cancer Resources

• 📚 POC Learning Center
• 🎓 POC Academy
• 🩺 1-on-1 Cancer Coaching
• ▶️ POC YouTube Channel
• 🎙️ POC Podcast Playlist
• 💊 UltraBotanica / ONCO-ADJUNCT™ Pathways — 10-20% Discount
• 💊 Designs for Health Supplements 10% Discount
• 💊 Fullscript — 10% off
• 💊 Flourish Nutraceuticals — code PREVAIL5 5% Discount

Together — We Prevail Over Cancer!™ Prevail. Assess. Don't Guess.™

References

1. Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol. 2015;54(7):961-970. https://pubmed.ncbi.nlm.nih.gov/25984930/
2. Zhang Z, Lin G, Yan Y, et al. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep. 2015;5:9800. https://pubmed.ncbi.nlm.nih.gov/25902419/
3. Van Wilpe S, Koornstra R, Den Brok M, et al. Lactate dehydrogenase: a marker of diminished antitumor immunity. Oncoimmunology. 2020;9(1):1731942. https://pubmed.ncbi.nlm.nih.gov/32158624/
4. Cui Y, Li C, Sang F, et al. Natural products targeting glycolytic signaling pathways — an updated review on anti-cancer therapy. Front Pharmacol. 2022;13:1035882. https://pubmed.ncbi.nlm.nih.gov/36339566/
5. Yao H, Yang F, Li Y. Natural products targeting human lactate dehydrogenases for cancer therapy: a mini review. Front Chem. 2022;10:1013670. https://pubmed.ncbi.nlm.nih.gov/36247675/
6. Wulaningsih W, Holmberg L, Garmo H, et al. Serum lactate dehydrogenase and survival following cancer diagnosis. Br J Cancer. 2015;113(9):1389-1396. https://pubmed.ncbi.nlm.nih.gov/26469834/ 
7. Barlogie B, Smallwood L, Smith T, Alexanian R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med. 1989;110(7):521-525. https://www.acpjournals.org/doi/10.7326/0003-4819-110-7-521 
8. Brown NJ, Higham SE, Perunovic B, et al. Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers. PLoS One. 2013;8(2):e57697. https://pubmed.ncbi.nlm.nih.gov/23437403/
9. Wu Y, Lu C, Pan N, et al. Serum lactate dehydrogenase activities as systems biomarkers for 48 types of human diseases. Sci Rep. 2021;11(1):12997. https://pubmed.ncbi.nlm.nih.gov/34155288/
10. Farhana A, Lappin SL. Biochemistry, Lactate Dehydrogenase. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK557536/
11. Mayo Clinic Laboratories. Lactate Dehydrogenase (LDH), Serum — Clinical and Interpretive Information. Mayo Medical Laboratories Test Catalog. https://www.mayocliniclabs.com/test-catalog/overview/8344
12. Klein R, Nagy O, Tóthová C, Chovanová F. Clinical and diagnostic significance of lactate dehydrogenase and its isoenzymes in animals. Vet Med Int. 2020;2020:5346483. https://pubmed.ncbi.nlm.nih.gov/32607139/
13. Kotoh K, Kato M, Kohjima M, et al. Lactate dehydrogenase production in hepatocytes is increased at an early stage of acute liver failure. Exp Ther Med. 2011;2(2):195-199. https://pubmed.ncbi.nlm.nih.gov/22977488/
14. Kobayashi Y, Takeuchi T, Hosoi T, Loeppky JA. Evaluation of exercise intensity indicated by serum lactate dehydrogenase activity in healthy adults. Sangyo Igaku. 1994;36(1):17-23. https://pubmed.ncbi.nlm.nih.gov/8184626/
15. Wu Y, Lu C, Pan N, et al. Serum lactate dehydrogenase activities as systems biomarkers for 48 types of human diseases. Sci Rep. 2021;11(1):12997. https://pubmed.ncbi.nlm.nih.gov/34155288/
16. Henry BM, Aggarwal G, Wong J, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med. 2020;38(9):1722-1726. https://pubmed.ncbi.nlm.nih.gov/32738466/
17. Han Y, Zhang H, Mu S, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY). 2020;12(12):11245-11258. https://pubmed.ncbi.nlm.nih.gov/32633729/
18. Galasso PJ, Litin SC, O'Brien JF. The macroenzymes: a clinical review. Mayo Clin Proc. 1993;68(4):349-354. https://pubmed.ncbi.nlm.nih.gov/7681133/

© 2026 Keith Bishop, Prevail Over Cancer LLC. All rights reserved. prevailovercancer.com